Eli Lilly, Mounjaro and Zepbound
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit
Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off Shelves
Eli Lilly & Co. raised its annual outlook for sales and profit as the company races to satisfy soaring demand for its blockbuster weight-loss and diabetes drugs.
All Eyes Are on Zepbound Sales as Lilly Reports Earnings
Lilly shares are up 82% over the past 12 months and 26% so far this year. Investors, and the general public, have been extraordinarily enthusiastic about the company’s weight-loss drug Zepbound, which the company also sells as a treatment for Type 2 diabetes under the name Mounjaro.
Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Eli Lilly’s stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro, Zepbound
Eli Lilly shares popped early Tuesday after the drugmaker reported first-quarter profit that topped estimates amid strong demand for diabetes and weight-loss drugs.
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs soar
Then $75 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Discover Magazine on MSN3h
The Difference Between Zepbound and Ozempic, and How They Work
The active ingredients in these popular type 2 diabetes treatments are being used to treat a wide range of health conditions.
Benefits Pro6h
Weight loss drug shortage: Zepbound and Wegovy in short supply, says FDA
Most doses of Zepbound have limited availability because of "demand increase for the drug," while only the highest dose of ...
FiercePharma5h
Facing pricing pressure from Lilly's Zepbound, Novo Nordisk scales Wegovy supply
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...
Everyday Health on MSN1d
Wegovy and Zepbound Shortages Will Last Until Summer
The FDA anticipates limited availability of most doses of the GLP-1 weight loss drugs Wegovy and Zepbound at least through ...
Popular weight loss drugs in tight supply as Zepbound shortage could last through June
Weight loss drugs, including Wegovy and Zepbound, are still in tight supply as a shortage of the latter could last through ...
Weight Loss Drug Zepbound May Help Sleep Apnea, Study Finds
The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...
Healthline13d
Zepbound Weight Loss Drug May Help Relieve Sleep Apnea Symptoms
In a new study, people with obesity who received weight-loss drug Zepbound saw a greater average reduction in sleep apnea ...
Inside Edition22h
How Diabetes Patients Are Impacted by Drug Shortage
Some people are having a really tough time finding their weight-loss medication. Kayla Donatucci drove 400 miles roundtrip, ...